Neuroplasticity Therapy for Depression

70% remission
in two weeks^*

A new class of depression treatment.

Our medical device, Haven™, is designed to restore neuroplasticity to rapidly treat Major Depressive Disorder. A daily 30-minute session to unlock a mechanism grounded in neuroscience.

* Results based on early feasibility studies with HAM-D validated patients.

The status quo is failing millions.

0M+

people globally live with depression

average remission rate of traditional antidepressants

of patients discontinue due to side effects or relapse

For decades, depression treatment has relied on chemical rebalancing: SSRIs, SNRIs, and escalating doses.

Depression is not simply a chemical imbalance.
It is a structural problem in the brain.
To treat rigidity, we must restore flexibility.

† Source: World Health Organization, 2023.

Rapid neuroplasticity therapy for depression.

Haven™ is a medical headset that delivers precision visual neuromodulation to restore the brain's natural plasticity. In depression, biological scaffolds called perineuronal nets lock neural circuits into rigid, negative patterns. Haven™ delivers precise 60 Hz light stimulation through the eyes targeting the brain's immune cells to transiently open these structures.

Stimulate

Haven™ delivers precise 60 Hz visual neuromodulation through a daily 30-minute session.

Restore

The brain's immune cells are activated to transiently open perineuronal nets and restore synaptic plasticity.

Recover

New, healthy neural connections form. Depression symptoms reduce rapidly. No drugs. No severe side effects.

Explore the science →

Patient

"The sessions were very relaxing, and I felt noticeably better after just a few days."

Female, 35

Patient, Brazil

Clinician

"The device is very comfortable and easy to use, and requires very little help from us to get the patient set up."

Clinical Neuropsychologist, Research Faculty

NYU Langone Health, U.S.

Patient

"My sleep really improved, I was able to sleep much better at night."

Male, 40

Patient, U.S.

Clinician

"If you can get us more devices, we're very interested to use them on more patients."

Psychiatrist, Clinical Faculty

UT Southwestern Medical Center, U.S.

Clinician

"We didn't expect to see such a strong and quick effect, it was really surprising."

Psychiatrist, Clinical Researcher

Sau Paulo University, Brazil

Patient

"I felt like I had more energy to do things I'd usually avoid, like meeting my friends for lunch."

Female, 38

Patient, Brazil

Patient

"The sessions were very relaxing, and I felt noticeably better after just a few days."

Female, 35

Patient, Brazil

Clinician

"The device is very comfortable and easy to use, and requires very little help from us to get the patient set up."

Clinical Neuropsychologist, Research Faculty

NYU Langone Health, U.S.

Patient

"My sleep really improved, I was able to sleep much better at night."

Male, 40

Patient, U.S.

Clinician

"If you can get us more devices, we're very interested to use them on more patients."

Psychiatrist, Clinical Faculty

UT Southwestern Medical Center, U.S.

Clinician

"We didn't expect to see such a strong and quick effect, it was really surprising."

Psychiatrist, Clinical Researcher

Sau Paulo University, Brazil

Patient

"I felt like I had more energy to do things I'd usually avoid, like meeting my friends for lunch."

Female, 38

Patient, Brazil

70% remission
in two weeks^*

The status quo is failing millions.

Rapid neuroplasticity therapy for depression.

Early clinical results.^*

Clinicians and patients speak.

Latest from Syntropic.

Reopening the Brain’s Window of Plasticity

Syntropic Honored at the U.S. Embassy Vienna

Syntropic Medical completes Phase IIa LUX study of HAVEN™, an investigational, non-invasive light-based approach for depression

Syntropic: Klosterneuburger MedTech startet Kooperationen in Brasilien und New York

Syntropic Medical publishes first-in-human study on novel light therapy technology in PLOS One

Best of Biotech 2025 Winner

Rapid Neuroplasticity therapy for depression.

70% remissionin two weeks*

The status quo is failing millions.

Rapid neuroplasticity therapy for depression.

Early clinical results.*

Clinicians and patients speak.

Latest from Syntropic.

Reopening the Brain’s Window of Plasticity

Syntropic Honored at the U.S. Embassy Vienna

Syntropic Medical completes Phase IIa LUX study of HAVEN™, an investigational, non-invasive light-based approach for depression

Syntropic: Klosterneuburger MedTech startet Kooperationen in Brasilien und New York

Syntropic Medical publishes first-in-human study on novel light therapy technology in PLOS One

Best of Biotech 2025 Winner

Rapid Neuroplasticity therapy for depression.

70% remission
in two weeks^*

Early clinical results.^*